Rigel Pharmaceuticals Inc. (RIGL)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1034842 · fiscal year ends in Dec
Closing price $51.45 on 29 Oct 2026; 52-week range $25.44 to $51.45.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $276.8M
- Revenue growth
- 3.3%
- Net income, last twelve months
- $321.9M
- Earnings per share
- $16.32
- Gross margin
- 91.4%
- Operating margin
- 31.5%
- Net margin
- 116.3%
- Return on equity
- 75.7%
- Market value
- $961.1M
- Price to earnings
- 3.2x
- Cash
- $60.8M
- Debt
- $40.0M
- Debt to equity
- 0.09
- Shares outstanding
- 18.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $294.3M | $125.5M | $367.0M | $19.48 | – | 10-K filed 3 Mar 2026 |
| FY2024 | 31 Dec 2024 | $179.3M | $24.2M | $17.5M | $0.99 | – | 10-K filed 4 Mar 2025 |
| FY2023 | 31 Dec 2023 | $116.9M | -$20.5M | -$25.1M | -$1.40 | – | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $120.2M | -$55.5M | -$58.6M | -$3.40 | -$74.2M | 10-K filed 7 Mar 2023 |
| FY2021 | 31 Dec 2021 | $149.2M | -$12.5M | -$17.9M | -$1.10 | $5.3M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $78.7M | $17.3M | $0.88 |
| Q1 FY2026 | 31 Mar 2026 | $58.8M | $8.7M | $0.44 |
| Q4 FY2025 | 31 Dec 2025 | $69.8M | $268.1M | $13.54 |
| Q3 FY2025 | 30 Sep 2025 | $69.5M | $27.9M | $1.46 |
| Q2 FY2025 | 30 Jun 2025 | $101.7M | $59.6M | $3.28 |
| Q1 FY2025 | 31 Mar 2025 | $53.3M | $11.4M | $0.63 |
| Q4 FY2024 | 31 Dec 2024 | $57.6M | $14.3M | $0.80 |
| Q3 FY2024 | 30 Sep 2024 | $55.3M | $12.4M | $0.70 |
Company events
The newest 8-K filings of 236 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 1 Jul 2026 | 8-K | Leadership change | 5.02 |
| 17 Jun 2026 | 8-K | Deal completed | 2.01 |
| 20 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
| 12 May 2026 | 8-K | Material agreement | 1.01 |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 |
| 21 Apr 2026 | 8-K | Agreement ended | 1.02 |
| 3 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Feb 2026 | 8-K | Leadership change | 5.02 |
| 12 Jan 2026 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 10 Dec 2025 | 8-K | Other events | 8.01, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 557 held.
| Filed | Form | Period |
|---|---|---|
| 4 Aug 2026 | S-8 | – |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 1 Jul 2026 | 8-K | 25 Jun 2026 |
| 17 Jun 2026 | 8-K | 11 Jun 2026 |
| 20 May 2026 | 8-K | 14 May 2026 |
| 12 May 2026 | 8-K | 11 May 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 21 Apr 2026 | 8-K | 16 Apr 2026 |
| 3 Apr 2026 | DEFA14A | – |
| 3 Apr 2026 | DEF 14A | 14 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 22 Jun 2026 | Ali-Jackson Kamil, Director | Sale under a trading plan | 2,500 | $35.00 | $87.5K | 10,125 | 24 Jun 2026 |
| 26 May 2026 | Ali-Jackson Kamil, Director | Sale under a trading plan | 2,500 | $29.17 | $72.9K | 12,625 | 28 May 2026 |
| 20 Feb 2026 | Moos Walter H, Director | Sale outside a trading plan | 4,000 | $36.36 | $145.4K | 12,722 | 24 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 22 Jun 2026 | Ali-Jackson Kamil, Director | 2,500 | $87.5K | 22 Jun 2026 |
| 26 May 2026 | Ali-Jackson Kamil, Director | 2,500 | $72.9K | 26 May 2026 |
| 20 Feb 2026 | MOOS WALTER H, Director | 4,000 | $145.4K | 20 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Armistice Capital, LLC | 13G amended | 8.95% | 1.7M |
| 13 Aug 2026 | Soleus Capital Master Fund, L.P. | 13G amended | 9.9% | 1.8M |
| 15 May 2026 | Armistice Capital, LLC | 13G | 6.93% | 1.3M |
| 7 May 2026 | Soleus Capital Master Fund, L.P. | 13G | 5.2% | 968.1K |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 6% | 1.1M |
| 14 Nov 2025 | Armistice Capital, LLC | 13G amended | 3.99% | 724.0K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.7M | -4.3% | 12.8 |
| 30 Sep 2026 | 2.9M | -10.54% | 11.14 |
| 15 Sep 2026 | 3.2M | +0.3% | 15.83 |
| 31 Aug 2026 | 3.2M | -0.66% | 9.11 |
| 14 Aug 2026 | 3.2M | +3.57% | 9.76 |
| 31 Jul 2026 | 3.1M | -2.04% | 10.55 |
| 15 Jul 2026 | 3.2M | -2.93% | 7.87 |
| 30 Jun 2026 | 3.3M | -5.96% | 7.18 |
Funds that hold it
From each fund's latest Form 13F.
181 funds held it at 30 Jun 2026: 80 added and 55 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | $75.9M | +170,911 |
| Soleus Capital Management, L.P. | 1,843,504 | $72.1M | +1,833,504 |
| Armistice Capital, LLC | 1,672,000 | $65.4M | +392,000 |
| State Street Corp. | 1,039,994 | $40.7M | -80,244 |
| Vanguard Capital Management LLC | 785,107 | $30.7M | +20,914 |
| American Century Companies Inc. | 741,718 | $29.0M | +197,287 |
| LSV Asset Management | 721,666 | $28.2M | +120,159 |
| Acadian Asset Management LLC | 591,686 | $23.1M | -74,740 |
| D. E. Shaw & Co., Inc. | 542,539 | $21.2M | +96,861 |
| Geode Capital Management, LLC | 483,175 | $18.9M | +42,549 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B